Overview
Herpangina is a viral illness predominantly affecting young children, characterized by fever, sore throat, and small, painful blisters or ulcers in the back of the throat and on the soft palate. The condition is primarily caused by enteroviruses, with Coxsackievirus B species, particularly Coxsackievirus B3, being the most frequently implicated pathogens. Outbreaks can occur rapidly in settings with close contact among children, such as daycare centers and orphanages, underscoring the contagious nature of the disease. Understanding the pathophysiology, epidemiology, clinical presentation, diagnosis, and management of herpangina is crucial for effective clinical management and containment of outbreaks.
Pathophysiology
Herpangina is fundamentally a viral infection, with Coxsackievirus B3 identified as a key causative agent in a significant proportion of cases. Studies have shown that Coxsackievirus B3 was detected in 64% of throat swabs from affected individuals, highlighting its predominant role in herpangina beyond the more commonly recognized Group A Coxsackieviruses [PMID:2549494]. Beyond direct viral isolation, serological evidence further supports the involvement of Coxsackievirus B3 in additional cases where viral culture might have been negative or not performed, indicating a broader spectrum of infection than initially apparent through clinical sampling alone. This dual evidence from both virological and serological methods underscores the importance of comprehensive diagnostic approaches in confirming Coxsackievirus B3 as the etiological agent.
The virus typically enters through mucosal surfaces, likely via the oropharyngeal route, leading to localized inflammation and vesicular lesions characteristic of herpangina. The rapid onset and specific tropism for mucosal tissues explain the localized yet symptomatic nature of the disease, affecting primarily the posterior pharynx and soft palate. This pathophysiology not only guides diagnostic efforts but also informs preventive measures aimed at reducing mucosal exposure to infectious agents in high-risk environments.
Epidemiology
Herpangina exhibits a notable propensity for rapid spread, particularly among young children in communal settings. An illustrative outbreak observed in a welfare home involved 81% (25 out of 31) infants over a span of just five days, emphasizing the explosive nature of transmission within confined populations [PMID:2549494]. This rapid dissemination suggests that the virus can spread efficiently through close contact, potentially via small particle aerosols, which aligns with the highly contagious nature of enteroviral infections. The setting of the outbreak—a welfare home—highlights vulnerable populations where hygiene practices and living conditions may not always be optimal, facilitating such swift transmission.
Understanding the epidemiological patterns is crucial for implementing targeted public health interventions. Schools and childcare facilities should maintain stringent hygiene protocols, including frequent handwashing and disinfection of shared surfaces, to mitigate the risk of outbreaks. Surveillance systems that monitor clusters of febrile illnesses with pharyngeal symptoms can aid in early detection and containment, preventing wider spread within communities.
Clinical Presentation
Herpangina typically affects children with an average age of onset around 2.5 years, indicating a predilection for preschool-aged children [PMID:33878461]. The clinical presentation is often characterized by a sudden onset of high fever, sore throat, and characteristic vesicular or ulcerative lesions in the posterior pharynx and soft palate. Among a cohort of 22 patients with confirmed Coxsackievirus B3 infections, the majority exhibited classic herpangina symptoms, while others presented with milder forms such as pharyngitis or occasional vesicular lesions, reflecting the variable clinical expression of the virus [PMID:2549494]. This variability underscores the importance of clinical suspicion and thorough examination, especially in settings where herpangina is prevalent.
Beyond the primary symptoms, affected children may also experience malaise, anorexia, and in some cases, gastrointestinal symptoms like vomiting or diarrhea, though these are less common. The presence of painful oral lesions can significantly impact feeding and hydration, necessitating careful monitoring and supportive care to prevent dehydration, particularly in younger children. Recognizing these diverse presentations is essential for timely diagnosis and appropriate management, ensuring that children receive necessary symptomatic relief and supportive treatments.
Diagnosis
Diagnosing herpangina involves a combination of clinical evaluation and laboratory confirmation. Throat swabs are a critical diagnostic tool, with Coxsackievirus B3 isolated from 64% of cases, providing direct evidence of viral presence [PMID:2549494]. However, viral culture may yield negative results in some instances due to the transient nature of viral shedding or technical limitations. Serological methods, including antibody detection tests, play a complementary role by identifying past or current infections where viral culture might be inconclusive. These combined approaches enhance diagnostic accuracy, ensuring that cases are correctly attributed to Coxsackievirus B3 or other enteroviruses when necessary.
In clinical practice, the absence of specific laboratory facilities might necessitate reliance on clinical criteria alone, particularly in resource-limited settings. Key clinical features such as fever, pharyngeal lesions, and epidemiological context (e.g., recent outbreaks in the community) guide presumptive diagnosis until confirmatory tests can be conducted. Early and accurate diagnosis is pivotal for initiating appropriate care and preventing unnecessary antibiotic use, which is ineffective against viral infections like herpangina.
Management
The management of herpangina primarily focuses on supportive care to alleviate symptoms and ensure adequate hydration, as there are no specific antiviral treatments approved for enteroviral infections like Coxsackievirus B3. However, recent studies have explored novel therapeutic approaches that show promise. One such intervention involves the local application of recombinant interferon α-2b spray, which demonstrated significant clinical benefits in pediatric patients aged 1-7 years [PMID:33878461]. Compared to Ribavirin aerosol, the use of recombinant interferon α-2b led to a notably faster resolution of fever within 72 hours (98.5% vs 94.3%, P = 0.004) and improved oral symptoms (46.7% vs 37.1%, P = 0.011). Importantly, this treatment was well-tolerated, with no adverse reactions reported, highlighting its safety profile in this vulnerable population.
Supportive care measures include maintaining hydration through oral fluids or, if necessary, intravenous hydration, especially in cases where oral intake is severely compromised due to painful lesions. Pain management with analgesics such as acetaminophen can help reduce fever and discomfort. Ensuring adequate nutrition and rest is also crucial for recovery. In settings where outbreaks occur, implementing strict hygiene practices and isolating affected individuals can help prevent further spread within the community.
Key Recommendations
References
1 Ye YZ, Dou YL, Hao JH, Zhou L, Lin AW, Wang SN et al.. Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021. link 2 Nakayama T, Urano T, Osano M, Hayashi Y, Sekine S, Ando T et al.. Outbreak of herpangina associated with Coxsackievirus B3 infection. The Pediatric infectious disease journal 1989. link
2 papers cited of 3 indexed.